Renaissance Capital logo

VIR News

Biotech IPOs close to beating Covid-19

ABCL

Less than nine months after Covid-19 became an unwelcome household word, the virus may be close to being vanquished. A number of biotech IPOs are key players in vaccine development. Most prominent is headline grabber Moderna (MRNA), which went public in December 2018. However, BioNTech (BNTX), an October 2019 IPO, and Pfizer may be first to get FDA approval. Vir...read more

US IPO Week Ahead: Another biotech plans to take on the IPO market

KROS

Biotechs are back as another early stage biotech, Keros Therapeutics (KROS), plans to take on the IPO market in the week ahead, following last week's successful debut of Zentalis Pharmaceuticals (ZNTL). Keros Therapeutics, a Phase 1 biotech developing novel treatments for hematological and musculoskeletal disorders, plans to raise...read more

Hard times for SoftBank in the IPO market

OCFT

The We Company (WE) isn’t SoftBank’s only dud. SoftBank has been a principal shareholder on two US IPOs this year, both of which are now underwater. This week’s IPO of Chinese software platform OneConnect Financial Technology (OCFT) would continue the streak. ...read more

US IPO Weekly Recap: Two big biotechs and a bank squeeze through the IPO window

BNTX

Three IPOs raised a combined $426 million this week, all pricing below the midpoint and finishing below issue. On average they returned a disappointing -13.5%. Despite lopping $1 billion off of its proposed valuation, Germany-based BioNTech (BNTX) became the ...read more